Warning! GuruFocus detected
1 Severe warning sign
with ACHL.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Achilles Therapeutics PLC
ISIN : US00449L1026
Share Class Description:
ACHL: ADRDescription
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 23.77 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -29.6 | |||||
| 3-Year EPS without NRI Growth Rate | -28.7 | |||||
| 3-Year FCF Growth Rate | -10.7 | |||||
| 3-Year Book Growth Rate | -9.4 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 77.84 | |||||
| 9-Day RSI | 77.35 | |||||
| 14-Day RSI | 75.81 | |||||
| 3-1 Month Momentum % | 21.05 | |||||
| 6-1 Month Momentum % | 45.26 | |||||
| 12-1 Month Momentum % | 7.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.04 | |||||
| Quick Ratio | 6.04 | |||||
| Cash Ratio | 4.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.4 | |||||
| Shareholder Yield % | 5.83 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -51.86 | |||||
| ROA % | -45.41 | |||||
| ROIC % | -268.13 | |||||
| 3-Year ROIIC % | 307.72 | |||||
| ROC (Joel Greenblatt) % | -575.05 | |||||
| ROCE % | -55 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.59 | |||||
| Price-to-Tangible-Book | 0.59 | |||||
| EV-to-EBIT | 0.24 | |||||
| EV-to-EBITDA | 0.24 | |||||
| EV-to-FCF | 0.93 | |||||
| Price-to-Net-Current-Asset-Value | 0.66 | |||||
| Price-to-Net-Cash | 0.91 | |||||
| Earnings Yield (Greenblatt) % | 416.67 | |||||
| FCF Yield % | -27.82 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ACHL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Achilles Therapeutics PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.65 | ||
| Beta | 1.5 | ||
| 3-Year Sharpe Ratio | -0.1 | ||
| 3-Year Sortino Ratio | -0.14 | ||
| Volatility % | 71.61 | ||
| 14-Day RSI | 75.81 | ||
| 14-Day ATR ($) | 0.031798 | ||
| 20-Day SMA ($) | 1.41475 | ||
| 12-1 Month Momentum % | 7.81 | ||
| 52-Week Range ($) | 0.63 - 1.51 | ||
| Shares Outstanding (Mil) | 41.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Achilles Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Achilles Therapeutics PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Achilles Therapeutics PLC Frequently Asked Questions
What is Achilles Therapeutics PLC(ACHL)'s stock price today?
The current price of ACHL is $1.48. The 52 week high of ACHL is $1.51 and 52 week low is $0.63.
When is next earnings date of Achilles Therapeutics PLC(ACHL)?
The next earnings date of Achilles Therapeutics PLC(ACHL) is 2025-04-04 Est..
Does Achilles Therapeutics PLC(ACHL) pay dividends? If so, how much?
Achilles Therapeutics PLC(ACHL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers